Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB1 | P15086 | 1/20 | 0.32 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.32 |
| ▸ | SIRT1 | Q96EB6 | 3/20 | 0.32 |
| ▸ | SIRT2 | Q8IXJ6 | 4/20 | 0.31 |
| ▸ | CA1 | P00915 | 2/20 | 0.31 |
| ▸ | CA2 | P00918 | 2/20 | 0.31 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.31 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.30 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13367216 | 0.93 | SIRT5 (0.33) | CPB1CPB2SIRT1SIRT2CA1 | |
| SCHEMBL327667 | 0.92 | SIRT1 (0.36) | CPB1CPB2SIRT1SIRT2CA1 | |
| SCHEMBL20010470 | 0.90 | SIRT2 (0.39) | CPB1CPB2SIRT1SIRT2SIRT5 | |
| SCHEMBL2610729 | 0.89 | SIRT2 (0.35) | CPB1CPB2SIRT1SIRT2CA1 | |
| SCHEMBL11955676 | 0.88 | SIRT2 (0.37) | CPB1CPB2SIRT1SIRT2SIRT5 | |
| SCHEMBL12497446 | 0.86 | CPB1 (0.36) | CPB1CPB2SIRT1SIRT2CA1 | |
| SCHEMBL10310593 | 0.81 | SIRT2 (0.41) | CPB1CPB2SIRT1SIRT2SIRT5 | |
| SCHEMBL10167189 | 0.81 | AKT1 (0.37) | SIRT1SIRT2 | |
| SCHEMBL14542727 | 0.78 | AKT1 (0.36) | SIRT1SIRT2SIRT5 | |
| SCHEMBL12509123 | 0.78 | SIRT1 (0.34) | CPB1CPB2SIRT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8293869-B2 | Polymer conjugates of GLP-1 | NEKTAR THERAPEUTICS (US) | 2012-10-23 | — | — | US | disclosed |
| US-8273339-B2 | Polymer-based compositions and conjugates of antimicrobial agents | NEKTAR THERAPEUTICS (US) | 2012-09-25 | — | — | US | disclosed |
| US-8143378-B2 | Polymer factor VIII moiety conjugates | NEKTAR THERAPEUTICS (US) | 2012-03-27 | — | — | US | disclosed |
| US-7863421-B2 | Binding element comprising polyethylene glycol and antihemophilic factor for use in treatment of hemophilia | NEKTAR THERAPEUTICS (US) | 2011-01-04 | — | — | US | disclosed |
| US-7858749-B2 | Water soluble polyoxyethylene glylcol polyvinylpyrrolidone, polyvinyl alcohol, polyoxazoline, and/or polyacryloylmorpholine, conjugated to antihemophilic factor | NEKTAR THERAPEUTICS (US) | 2010-12-28 | — | — | US | disclosed |
| US-20100249033-A1 | POLYMER FACTOR IX MOIETY CONJUGATES | NEKTAR THERAPEUTICS (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100210505-A1 | POLYMER CONJUGATES OF GLP-1 | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2010-08-19 | — | — | US | disclosed |
| US-20100137511-A1 | POLYMER FACTOR IX MOIETY CONJUGATES | NEKTAR THERAPEUTICS (US) | 2010-06-03 | — | — | US | disclosed |
| US-20100130428-A1 | POLYMER FACTOR IX MOIETY CONJUGATES | NEKTAR THERAPEUTICS (US) | 2010-05-27 | — | — | US | disclosed |
| US-20100125049-A1 | POLYMER FACTOR VIII MOIETY CONJUGATES | NEKTAR THERAPEUTICS (US) | 2010-05-20 | — | — | US | disclosed |
| US-7714114-B2 | Conjugates of an EPO moiety and a polymer | NEKTAR THERAPEUTICS (US) | 2010-05-11 | — | — | US | disclosed |
| US-20090280550-A1 | Polymer-Factor IX Moiety Conjugates | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2009-11-12 | — | — | US | disclosed |
| US-7579444-B2 | Polymer-factor IX moiety conjugates | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2009-08-25 | — | — | US | disclosed |
| US-20090041714-A1 | Binding element comprising polyethylene glycol and antihemophilic factor for use in treatment of hemophilia | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2009-02-12 | — | — | US | disclosed |
| US-20080058504-A1 | Water soluble polyoxyethylene glylcol polyvinylpyrrolidone, polyvinyl alcohol, polyoxazoline, and/or polyacryloylmorpholine, conjugated to antihemophilic factor | NEKTAR THERAPEUTICS | 2008-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090041714-A1 | Binding element comprising polyethylene glycol and antihemophilic factor for use in treatment of hemophilia | F13B, F8, F13A1 | CPB1 232/4885CPB2 219/4885SIRT1 4665/4885 |
| US-20100125049-A1 | POLYMER FACTOR VIII MOIETY CONJUGATES | F8, F9, F13B | CPB1 158/4885CPB2 137/4885SIRT1 4441/4885 |
| US-20100210505-A1 | POLYMER CONJUGATES OF GLP-1 | GLP1R, GIPR, NGLY1 | CPB1 1663/4885CPB2 3064/4885SIRT1 105/4885 |
| US-20100249033-A1 | POLYMER FACTOR IX MOIETY CONJUGATES | F9, F13A1, F8 | CPB1 277/4885CPB2 338/4885SIRT1 3966/4885 |
| US-20080058504-A1 | Water soluble polyoxyethylene glylcol polyvinylpyrrolidone, polyvinyl alcohol, polyoxazoline, and/or polyacryloylmorpholine, conjugated to antihemophilic factor | F8, F13A1, F13B | CPB1 1156/4885CPB2 686/4885SIRT1 4397/4885 |
| US-20100130428-A1 | POLYMER FACTOR IX MOIETY CONJUGATES | F9, F13A1, F8 | CPB1 277/4885CPB2 338/4885SIRT1 3966/4885 |
| US-20100137511-A1 | POLYMER FACTOR IX MOIETY CONJUGATES | F9, F13A1, F8 | CPB1 277/4885CPB2 338/4885SIRT1 3966/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.